Lecet, containing the active ingredient cetirizine, is generally categorized as a second-generation H1 antihistamine. Its main therapeutic domain is in the symptomatic management of allergic reactions. This medicine is commonly used to help with symptoms associated with acute or episodic changes resulting from seasonal and perennial allergies. It is applied in addressing core symptoms related to heightened physiological activity, including sneezing, a runny nose, itchy or watery eyes, and discomfort in the throat or nose. Lecet is considered relevant treatment for conditions characterized by periods of heightened symptoms, such as the skin manifestations of chronic urticaria (hives). “It supports general well-being during symptomatic phases by easing the associated itching and redness.” This approach may assist with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Itching and Redness Caused by Hives.

Regulatory References

1. NIH MedlinePlus overview on Cetirizine

Official Eligibility: Who Can and Cannot Use Levocetirizine (Lecet)

Eligibility for Lecet is strictly determined by regulatory authorities and is based primarily on patient age, renal function, and hypersensitivity status.

Contraindications (Must Not Use)

Condition/Population	Restriction
Hypersensitivity	Known allergy to levocetirizine, cetirizine, or any piperazine derivatives
Severe Renal Impairment	End-stage renal disease (Creatinine Clearance < 10 mL/min), or patients on hemodialysis
Children (6 months–11 years)	Any degree of impaired renal function (use is prohibited)

Restricted and Non-Established Use

• Infants under 6 months: Safety and efficacy are not established, and use is generally not recommended.
• Renal Impairment (Adults/Adolescents): Use is restricted and requires a dose adjustment based on the degree of kidney function impairment.
• Pregnancy and Lactation: Use during pregnancy should occur only if clearly necessary. Use while breastfeeding is generally not recommended as the substance is excreted in human milk.
• Urinary Retention Risk: Caution is advised for individuals with predisposing factors for urinary retention, such as prostatic hyperplasia.

Lecet Interactions with other medicines and products

Interacting Substances

Lecet (levocetirizine) can interact with substances that also cause Central Nervous System (CNS) depression. This additive effect means that the risk of experiencing reduced alertness, increased drowsiness, and impaired performance is greater when Lecet is used alongside these agents.

Interacting Categories and Products:

Category/Product	Interaction Outcome	Management Note
Alcohol (Ethanol)	Additive CNS depression, leading to impairment of alertness and performance.	Avoid use
Other CNS Depressants (e.g., sedatives, certain pain medicines, tranquilizers)	Additive CNS depression, potentially worsening side effects like dizziness or drowsiness.	Avoid concurrent use

Other Interaction Information

Patients taking Lecet should be aware of the potential for these combined effects, particularly when engaging in activities that require complete mental alertness and motor coordination, such as operating machinery or driving. Regulatory information strongly advises that concurrent use of Lecet with alcohol or other CNS depressants be avoided.

Studies suggest that levocetirizine is primarily eliminated by the kidneys as the unchanged drug, and it is unlikely to cause significant drug-drug interactions by inhibiting or inducing major liver drug-metabolizing enzymes.

How Lecet Works

---

Selective Blockade of Peripheral H1 Receptors

Levocetirizine's mechanism involves acting as a high-affinity inverse agonist that binds selectively to peripheral mathbfH1 receptors ( H1 R), physically preventing endogenous histamine from activating the receptor. This molecular blockade halts the G q/11 signaling cascade, reducing the resulting increased vascular permeability and stimulation of sensory nerves at the tissue level.

---

Sustained Physiological Control and Secondary Modulation

The prolonged duration of the physiological action is directly linked to the drug's slow dissociation kinetics, meaning the molecule unbinds very slowly from the H1 R after initial high-affinity binding. This sustained receptor occupancy maintains the inhibitory action for an extended period, contributing to sustained inhibition of the histamine-driven responses. Beyond H1 R antagonism, the drug engages secondary mechanisms by modulating the activity of inflammatory cells, such as eosinophils, and inhibiting the release of certain pro-inflammatory mediators. This broader influence modulates the overall intensity of the localized physiological response, promoting a more balanced state within the targeted pathways.

Levocetirizine is administered through the oral route and is provided in 5 mg tablets (scored) and as a liquid oral solution. The daily dose is taken in a single intake, typically once daily in the evening, and may be consumed with or without food. Tablets should be swallowed whole with liquid.

For adults and adolescents 12 years of age and older, the standard dose is 5 mg once daily, though a lower maintenance dose of 2.5 mg once daily may be sufficient for some patients. Children aged 6 to 11 years are administered a maximum recommended dose of 2.5 mg once daily. The oral solution is generally required for pediatric patients under 6 years, as the tablet formulation does not allow for the necessary dose of 1.25 mg once daily.

The required duration of use depends on the condition's pattern. For intermittent allergic rhinitis, treatment is managed according to symptom presence, allowing for cessation and subsequent restart if symptoms recur. For persistent allergic rhinitis, continuous daily administration is used throughout the period of allergen exposure.

A critical procedural requirement involves dose adjustment for renal impairment. For patients 12 years and older with decreased kidney function, the dose and frequency must be reduced based on the estimated creatinine clearance. For example, moderate renal impairment necessitates 2.5 mg once every other day. No dose adjustment is specified for patients with isolated hepatic impairment.

Research Evidence / Overview of studies for Lecet

This section provides a summary of the clinical research and scientific evidence for levocetirizine, focusing on the types of studies conducted, the outcomes measured, and where scientific uncertainty remains, as reported by authoritative regulatory and peer-reviewed sources.

---

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research into this medicine was evaluated in research exploring how symptoms change over time for seasonal and perennial allergies (hay fever). The research evidence includes short- and intermediate-term randomized controlled trials (RCTs) designed to compare the medicine against an inactive substitute (placebo) or sometimes against other active allergy medicines. The evidence was applied in studies examining patient-reported experiences of people with allergies.

Research primarily included adults, adolescents, and children who were experiencing fluctuating or unstable symptoms. The main outcomes related to physical discomfort that were monitored included changes in scores for sneezing, runny nose, itching, and watery eyes. Findings describe patterns observed in the studies regarding total symptom scores between the active medicine group and the placebo groups over short study periods. This evidence contributes to the broader evidence landscape, and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Chronic Urticaria (Hives)

For chronic idiopathic urticaria (CIU), or long-lasting hives, the evidence is largely derived from placebo-controlled, short-term RCTs. This research examined outcomes linked to inflammatory or irritative states in trials assessing short-term or episodic symptom patterns. Studies explored the medicine in populations of adults and children with conditions characterized by fluctuating or episodic manifestations.

In these studies, the main outcomes related to physical discomfort focused on objective and subjective assessments of skin symptoms. Specifically, studies examined outcomes by tracking changes in the severity of itching (pruritus) and the number and size of wheals (hives) using standardized rating scales. Reported outcomes primarily focused on the short-term control of visible skin and sensation symptoms.

---

Gaps in the Research: What is Still Uncertain

While the overall evidence base contributes to the broader evidence landscape, several limitations are noted. Long-term data are still emerging: There is limited information for long-term outcomes, as follow-up durations were limited in most primary RCTs, meaning the effects of continuous use over many years are not fully established. Data for specific groups, such as patients with multiple pre-existing health issues (comorbidities), remain insufficient to draw definitive conclusions. Comparative evidence is lacking: research has compared the medicine to certain other antihistamines, but more research exploring comparative effects would help contextualize patient experience.

Key Studies & References Public Assessment Report Decentralised Procedure: Levocetirizine Dihydrochloride (European regulatory summary used for indications and population data)

Common questions about Lecet (FAQ)

---

Q: How long does it take for Levocetirizine to start working?

Official product information indicates that the drug reaches its highest concentration in the bloodstream with a median time-to-maximum concentration (Tmax) of approximately 0.9 hours after dosing. This measurement reflects how quickly the medication becomes available in the body.

Q: What should I do if I miss a dose of Levocetirizine?

Patient counseling information states that if a dose is missed, taking it as soon as remembered is the general approach. However, if it is close to the time for the next dose, the regulatory instruction is to skip the missed dose and resume the usual schedule. Taking a double dose is not advised.

Q: Can Levocetirizine be taken while pregnant or breastfeeding?

Official documentation advises that use during pregnancy should only occur if clearly necessary. Regarding breastfeeding, the official label notes the substance is excreted in human milk. A decision must be made by a healthcare provider regarding whether to discontinue nursing or discontinue the drug.

Q: What is the maximum daily dose for an adult?

According to the official product label, the maximum recommended daily dose for adults and adolescents 12 years of age and older is 5 mg.

Q: Is Levocetirizine available over the counter (OTC)?

Yes, regulatory authorities have approved levocetirizine dihydrochloride for over-the-counter (OTC) use in certain formulations and strengths. This means it is approved to be sold without a prescription for the relief of allergy symptoms, as indicated on the package.

Q: Can Levocetirizine be crushed or split?

Official product information states that the 5 mg tablet is scored (marked with a line). The tablet can be split, but it should otherwise be swallowed whole with liquid.

Storage of Lecet

Lecet (levetiracetam) should be stored in its original container, tightly closed, and kept out of the reach of children. The medication should be stored at room temperature, typically between 59 F and 86 F (15 C and 30 C). It is important to protect the medicine from light, excess heat, and moisture. Avoid storing Lecet in the bathroom.

---

Disposal of Unused Lecet

If Lecet is expired or no longer needed, it should be disposed of promptly and safely. The preferred method for disposal of most unused or expired medicines is through a local drug take-back program or an authorized mail-back option. If these options are not readily available, follow the disposal instructions provided with the medicine. Do not flush Lecet down a toilet or pour it down a drain unless specifically instructed to do so by the medication guide. If throwing it in household trash, mix the medicine with an undesirable substance like used coffee grounds or cat litter, place the mixture in a sealed bag or container, and then discard it. Always scratch out all personal information on prescription labels before disposing of the container.